| Autor: |
Vorobyev PO; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia., Babaeva FE; National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, 125167 Russia., Panova AV; Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, 117971 Russia., Shakiba J; Moscow Institute of Physics and Technology, Dolgoprudny, 141701 Russia., Kravchenko SK; National Medical Research Center for Hematology, Ministry of Health of Russia, Moscow, 125167 Russia., Soboleva AV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia., Lipatova AV; Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.; lipatovaanv@gmail.com. |
| Abstrakt: |
Cancer is a leading causes of death. Despite significant success in the treatment of lymphatic system tumors, the problems of relapse, drug resistance and effectiveness of therapy remain relevant. Oncolytic viruses are able to replicate in tumor cells and destroy them without affecting normal, healthy tissues. By activating antitumor immunity, viruses are effective against malignant neoplasms of various nature. In lymphoproliferative diseases with a drug-resistant phenotype, many cases of remissions have been described after viral therapy. The current level of understanding of viral biology and the discovery of host cell interaction mechanisms made it possible to create unique strains with high oncoselectivity widely used in clinical practice in recent years. |
